- Roma stroll past Udinese as fans protest De Rossi sacking
- Horschel outduels McIlroy to win PGA Championship play-off
- Audiences summon 'Beetlejuice' to top of N. America box office for third week
- Stones salvages point for Man City against 10-man Arsenal
- Egypt fears 'all out' regional war: foreign minister to AFP
- Last-gasp Boniface gives Leverkusen victory, Stuttgart outclass Dortmund
- Scholz's party beats far-right AfD in east German state vote: projections
- Olympic champion Evenepoel retains world title in 'toughest time trial'
- Horschel's eagle beats McIlroy in PGA Championship play-off
- Mourners at commander's funeral express loyalty to Hezbollah
- Norris hails his 'mega' McLaren after dominant win at Singapore
- Monaco beat Le Havre to join PSG at the top of Ligue 1
- Scholz's party narrowly leads far-right AfD in east German state vote: exit polls
- New leftist president vows to 'rewrite Sri Lankan history'
- UN adopts pact to tackle volatile future for mankind
- Leclerc hails Ferrari fightback from torrid Singapore GP qualifying
- Belgian Evenepoel retains world title in 'toughest time trial'
- Sosa rescues point for Forest against Brighton
- Last-gasp Boniface gives Leverkusen victory over Wolfsburg in seven-goal thriller
- Swiss voters reject environment, pensions reforms: official results
- No fairytale ending for Ricciardo after 13 years in Formula One
- Israel and Hezbollah urged to step back from the brink
- What is the UN's 'Pact for the Future'?
- Norris dominates Singapore Grand Prix to cut Verstappen's title lead
- From bullets to ballots: Sri Lanka's comrade president-elect
- McLaren's Lando Norris wins Singapore GP to narrow F1 title race
- UN adopts pact promising to build 'brighter future' for humanity
- Military escalation not in Israel's 'best interest': White House
- Marxist leader declared Sri Lanka's president-elect
- Classes resume at Bangladesh university at heart of protests
- 'Barely anyone left': Sudan's El-Fasher devastated by fighting
- 'Warrior' Joshua vows to fight on despite Dubois mauling
- Martin extends MotoGP lead as Bastianini wins at Misano and Bagnaia crashes out
- New French government instantly under pressure on multiple fronts
- Australia's Brown adds world title to Olympic time trial gold
- Russian strike on Ukraine's Kharkiv wounds 21
- UK's Starmer rules out austerity as Labour conference opens
- Swiss voters reject environment, pensions reforms: projected results
- Israel says 'landed blows' on Hezbollah as Lebanon violence intensifies
- Roma CEO steps down amid anger over club icon De Rossi's sacking
- Incoming French government under pressure on multiple fronts
- Hezbollah rockets strike near Israel's Haifa as UN warns of 'catastrophe'
- Haddad Maia roars back to beat Kasatkina in Korea Open final
- All-rounder Ashwin powers India to 280-run Test win over Bangladesh
- Failed Springbok 'gamble' sets up rugby championship decider
- Lebanon strikes send Israelis to shelters as UN warns of 'catastrophe'
- Far-right AfD eyes new win in east German state vote
- Tony Popovic set to become new Socceroos coach - reports
- All-round Ashwin powers India to big Test win over Bangladesh
- NZ chase 275 to win first Sri Lanka Test after Patel bags six
Patients regain much weight after stopping new obesity drug: study
A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop treatment.
One study published Monday in the Journal of the American Medical Association provides an answer: much of the weight comes back, signaling patients may be locked into long term dependence on the drugs.
The research was based on weekly injections of tirzepatide, the compound in Eli Lilly's new weight loss drug Zepbound that was approved by the United States last month.
After 36 weeks, 670 adults achieved a notable mean weight loss of 20.9 percent.
The group was then split into two, with half continuing on Zepbound, and the other half given a placebo.
At 88 weeks, those on the placebo regained almost half of the weight they had lost, ending up 9.9 percent lower than their baseline.
Those on Zepbound continued to lose weight, ending 25.3 percent lower than where they had started.
The trial patients were mostly women and had a mean age of 48, with a mean weight at the outset was 107.3 kilograms (236.6 pounds).
All participants were encouraged to consume 500 calories less each day than they burnt and take at least 150 minutes of exercise per week.
Common side effects were gastrointestinal issues including nausea, diarrhea, constipation and vomiting, said the study.
- Growing evidence -
Study authors, led by Louis Aronne at Weill Cornell Medicine, New York, said the results "emphasize the need to continue pharmacotherapy to prevent weight regain and ensure the maintenance of weight reduction."
They added the latest research adds to four previous trials that showed "medications, including potent antiobesity medications such as semaglutide, have demonstrated that weight is substantially regained" after stopping treatment.
Semaglutide is the active ingredient in Novo Nordisk's Ozempic and Wegovy, which, like Zepbound, are examples of so-called "GLP-1 agonists" that work by mimicking the function of a hormone that secretes insulin, slows down the emptying of the stomach, and suppresses appetite.
Zepbound also contains another molecule that acts like the gut hormone GIP.
In response to the study, Lilly's Jeff Emmick said in a statement that "patients, providers and the public do not always understand obesity is a chronic disease that often requires ongoing treatment, which can mean that treatment is stopped once weight goals are met."
GLP-1 agonists have been found to cut the risk of cardiovascular disease associated with obesity -- but they also heighten the risk of gastrointestinal problems, studies show.
Though the rates of serious issues such as stomach paralysis are low, some experts fear that using the drugs for years or decades could change the benefit-to-risk calculus.
Cost can also be a disincentive. Zepbound costs $1,059.87 per month, and insurance companies often do not cover weight loss medications. Medicare, state subsidized insurance for the elderly, is barred from covering it.
D.Sawyer--AMWN